Drug resistance is a serious challenge for platinum anticancer drugs. Platinum complexes
may get over the drug resistance via a distinct mechanism of action. Cholesterol is a key …

To develop the next-generation Pt drug with remarkable activity and low toxicity to maximally
inhibit tumor growth, we optimized a Pt (II) thiosemicarbazone compound (C4) with …

Developing multifunctional platinum (IV) prodrugs via integrating bioactive pharmacophores
into one entity is an attractive strategy to ameliorate the defects of platinum (II) drugs. Herein …

Twenty new zinc (II) complexes with 8-hydroxyquinoline (H-Q1–H-Q6) in the presence of 1,
10-phenanthroline derivatives (D1–D10) were synthesized and formulated as [Zn (Q1) 2 …

To overcome the limitations of traditional platinum (Pt)-based drugs and further improve the
targeting ability and therapeutic efficacy in vivo, we proposed to design a human serum …

Both ruthenium-containing complexes and 8-quinolinoline compounds have emerged as a
potential novel agent for malignant tumor therapy. Here, three triphenylphosphine ruthenium …

A series of autophagy-targeted antimetastatic clioquinol (CLQ) platinum (IV) conjugates
were designed and prepared by incorporating an autophagy activator CLQ into the platinum …

We synthesized and analyzed nine unique copper (II) hydrazylpyridine salicylaldehyde and
1, 10-phenanthroline complexes,[Cu (L1a)(phen)](Cugdupt1),[Cu (L2a)(phen)]·(CH3CN) …

Developing multitarget platinum (IV) prodrugs is an important strategy to attenuate cisplatin
(CDDP) resistance in tandem with reduced toxicity. Herein, six novel ligustrazine-derived …

Objectives Remarkable potential of silver nanoparticles (NPs) makes its use efficient in both
biological as well as industrial applications. Post harvested NPs, free from other hazards …